Lifelight, a London, UK-based developer of a clinical grade remote patient monitoring platform, raised over $8m in funding to date.
The backers were not disclosed.
The company intends to use the funds to expand its development efforts.
Led by Laurence Pearce, CEO & founder, Lifelight is advancing a platform that allows smartphones and tablets to measure vital signs such as oxygen saturation, pulse, blood pressure, and breathing rate by looking into the device’s camera for approx. 40 seconds. Currently a CE Class I medical device, the company is working to deliver a CE Class II medical device and gain FDA clearance to get access to the US and other countries, as well.
Lifelight, which now employs over 40 people, has conducted three clinical trials and partners with telehealth organizations across multiple health sectors and geographies to embed the device into their platforms. One of them is Danish pharma company Novo Nordisk.